How to cite item

7-Chloroarctinone-b as a new selective PPARγ antagonist potently blocks adipocyte differentiation

  
@article{APS6431,
	author = {Yong-tao Li and Li Li and Jing Chen and Tian-cen Hu and Jin Huang and Yue-wei Guo and Hua-liang Jiang and Xu Shen},
	title = {7-Chloroarctinone-b as a new selective PPARγ antagonist potently blocks adipocyte differentiation},
	journal = {Acta Pharmacologica Sinica},
	volume = {30},
	number = {9},
	year = {2016},
	keywords = {},
	abstract = {Aim: Peroxisome proliferator-activated receptor gamma (PPARγ) is a therapeutic target for obesity, cancer and diabetes mellitus. In order to develop potent lead compounds for obesity treatment, we screened a natural product library for novel PPARγ antagonists with inhibitory effects on adipocyte differentiation.
Methods: Surface plasmon resonance (SPR) technology and cell-based transactivation assay were used to screen for PPARγ antagonists. To investigate the antagonistic mechanism of the active compound, we measured its effect on PPARγ/RXRα heterodimerization and PPARγ co-activator recruitment using yeast two-hybrid assay, Gal4/UAS cell-based assay and SPR based assay. The 3T3-L1 cell differentiation assay was used to evaluate the effect of the active compound on adipocyte differentiation.
Results: A new thiophene-acetylene type of natural product, 7-chloroarctinone-b (CAB), isolated from the roots of Rhaponticum uniflorum, was discovered as a novel PPARγ antagonist capable of inhibiting rosiglitazone-induced PPARγ transcriptional activity. SPR analysis suggested that CAB bound tightly to PPARγ and considerably antagonized the potent PPARγ agonist rosiglitazone-stimulated PPARγ-LBD/RXRα-LBD binding. Gal4/UAS and yeast two-hybrid assays were used to evaluate the antagonistic activity of CAB on rosiglitazone-induced recruitment of the coactivator for PPARγ. CAB could efficiently antagonize both hormone and rosiglitazone-induced adipocyte differentiation in cell culture.
Conclusion: CAB shows antagonistic activity to PPARγ and can block the adipocyte differentiation, indicating it may be of potential use as a lead therapeutic compound for obesity.},
	issn = {1745-7254},	url = {http://www.chinaphar.com/article/view/6431}
}